tiprankstipranks
Innovent Biologics’ Drugs Added to China’s Reimbursement List
Company Announcements

Innovent Biologics’ Drugs Added to China’s Reimbursement List

Innovent Biologics (HK:1801) has released an update.

Invest with Confidence:

Innovent Biologics has announced the inclusion of its drug Sintbilo (tafolecimab injection) and a new indication for Olverembatinib in China’s National Reimbursement Drug List for 2024, effective January 2025. This marks Innovent’s entry into the cardiovascular and metabolic field in China, potentially increasing the accessibility and affordability of these treatments for patients. Investors may find this development promising as it positions Innovent for growth in the Chinese pharmaceutical market.

For further insights into HK:1801 stock, check out TipRanks’ Stock Analysis page.

Related Articles
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App